Phillips-Medisize to Manufacture Wearable, Electronic-Enabled Combination Product
Phillips-Medisize, a Molex company, revealed its agreement with a biotechnology company to manufacture a wearable electronic-enabled combination product.
In an Oct. 22, 2019 press release, Phillips-Medisize, a Molex company, revealed its agreement with a biotechnology company to manufacture a wearable electronic-enabled combination product.
The combination drug product is currently in post-Phase III development. The wearable drug-device combination product is approximately the size of a hockey puck and is either adhered to the patient using an adhesive patch or is worn near the infusion site.
“This exciting new contract taps over 13 years of Phillips-Medisize’s combination product expertise, which includes cold chain drug handling and first programs with API handling. We have experience in manufacturing both combination and electronic-enabled drug delivery devices, and this is our first product submitted for FDA approval that includes both,” said Matt Jennings, CEO and president, Phillips-Medisize, in the press release.
Once regulatory approval is achieved, Phillips-Medisize will be contractually obliged to provide commercialization services from its manufacturing site based in Hudson, WI. It is anticipated that the product will launch during the second half of 2020.
Source: Phillips-Medisize
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
